Announcements Trials
Browse Landscape

Phase

Phase 1 5

Status

Completed 5

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Tumor-Agnostic 5Other solid neoplasm 2Thoracic 1Sarcoma 1Gynecologic 1

Conditions

Neoplasms 5

Interventions

pembrolizumab 94Paclitaxel 85Gemcitabine 83Carboplatin 79Docetaxel 60Cisplatin 58Bevacizumab 58Nivolumab 56Fluorouracil 47Capecitabine 46Magnetic Resonance Spectroscopy 44Radiotherapy 41Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 37Pemetrexed 34Leucovorin 34Biopsy 34atezolizumab 33Cetuximab 32Standard of Care 31Trastuzumab 28Cyclophosphamide 28Radiosurgery 27Blood Specimen Collection 27Specimen Handling 26Sorafenib 26Ipilimumab 26Everolimus 26olaparib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × AC 7700 × Tumor-Agnostic × Clear all
NCT01193595 2014-12-03

Dose-escalation, Safety, Pharmacokinetics Study of AVE8062 Combined With Bevacizumab in Patients With Advanced Solid Tumors

Sanofi

Phase 1 Completed
39 enrolled
Tumor-Agnostic

Neoplasms

NCT01095302 2013-10-16

Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel and Cisplatin in Patients With Solid Tumors

Sanofi

Phase 1 Completed
11 enrolled
Tumor-Agnostic

Neoplasms

NCT00719524 2013-03-11

AVE8062 in Combination With Platinum-taxane Doublet in Advanced Solid Tumor

Sanofi

Phase 1 Completed
71 enrolled
Tumor-Agnostic

Neoplasms

NCT01063946 2011-12-21

A Study to Investigate the Disposition of Radio-labeled AVE8062 Compound Administered as a 30-minute IV Infusion to Patients With Advanced Solid Tumor

Sanofi

Phase 1 Completed
3 enrolled
Tumor-Agnostic

Neoplasms

NCT01021150 2011-06-13

Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Cisplatin in Patients With Solid Tumors

Sanofi

Phase 1 Completed
12 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡